We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Electronic Nose Diagnoses Sleep Apnea with High Sensitivity

By LabMedica International staff writers
Posted on 29 Oct 2012
An electronic nose, which detects the presence of certain molecules in the breath of a patient, could be used to diagnose obstructive sleep apnea. More...
Electronic nose devices have been shown to distinguish between different diseases; they do this by analyzing the pattern of volatile organic compounds in breath samples

Scientists analyzed the breath of 40 sleep apnea patients and 20 healthy controls. Sleep apnea is associated with inflammation in the upper airways, which the investigators suggested could be detected by analysis of the exhaled breath of the patients. The study also aimed to assess whether the electronic nose could detect the effects of the standard treatment for sleep apnea i.e., continuous positive airway pressure (CPAP).

Questionnaires and sleep examinations confirmed sleep apnea in 40 patients. Throat washings were collected from patients to measure any improvement in their condition following treatment with CPAP. A statistical analysis model was used to calculate the accuracy of the electronic nose. The results found that the electronic nose could effectively diagnose sleep apnea. The statistical analysis showed that sleep apnea was detected with a sensitivity of 93%.

The study, which was published online on October 25, 2012 in the European Respiratory Journal could make the diagnosis of the condition quick and inexpensive compared to current methods. The gold standard used at present to identify sleep apnea is an overnight sleep test. This is technically demanding, time-consuming, and cost-intensive.

The lead author, Dr. Timm Greulich, from the Marburg Hospital (Germany) said, "This is the first time an electronic nose has been tested in the setting of sleep apnea diagnosis. The electronic nose could be useful in two ways. First, it can rule out the disease in a low prevalence population. Secondly, in a population with a high risk of sleep apnea, the device could be used to help decide who would need to undergo an overnight sleep examination. Following these results, we foresee that the use of an electronic nose could reduce costs by more appropriately selecting patients who require the sleep examination."

Related Links:

Marburg Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gastrointestinal Panel
Xpert® GI Panel
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.